

Indoco's Revenues Grow by 20.2% with improved EBIDTA margins

July 30, 2012

July, 30, 2012, Mumbai: Indoco Remedies Limited, a pharmaceutical company with global presence, recorded a growth of 20.2% in the revenues at Rs. 1511.6 million during the first quarter of FY 2012-13 as compared to Rs. 1257.4 million over the same quarter last year. The EBIDTA for the quarter was 19.3% at Rs. 292.2 million as compared to 16.3% at Rs. 205.0 million over the same quarter last year. The un-audited results for the first quarter of the financial year 2012-13 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on July 30, 2012.

Commenting on the performance, Ms. Aditi Panandikar, Managing Director said, "Indoco's Domestic Business has gathered momentum and registered an impressive growth during the quarter. Overall, the Company is doing fairly well and we are on track to achieve our intended objectives."

Mr. Sundeep V. Bambolkar, Jt. Managing Director added, "We are looking for qualitative growth in the International Business and have taken the cost control measures across functions to further improve our margins. With our own filing of ANDAs and Dossiers in the Regulated Markets, we shall be moving up the value-chain, resulting in higher profitability."

HIGHLIGHTS:

For First Quarter ended June 2012 of FY 2012-13

Net Revenues at Rs. 1511.6 million

EBIDTA at Rs. 292.2 million

Profit After Tax at Rs. 103.5 million

EPS at Rs. 1.12 (Face value of Rs.2/- per share after split & bonus)